natgillin/translations-raw huggingface dataset:
a group of symptoms due to cancer in the body such as high blood levels of calcium and cholesterol, and low blood levels of sugar (paraneoplastic syndrome)
kup simptoma zbog raka u tijelu, kao što su visoke razine kalcija i kolesterola u krvi i niska razina šećera (paraneoplastički sindrom)
A haemoglobin concentration above 12 g/dl should lead to discontinuation of erythropoietic agents.
Ako je koncentracija hemoglobina iznad 12 g/dl, treba prekinuti liječenje eritropoetskim lijekovima.
A half-life of approximately 6.2 to 8.7 hours has been reported in paediatric subjects with chronic renal failure following multiple dose intravenous administration of epoetin alfa.
U pedijatrijskih ispitanika s kroničnim zatajenjem bubrega zabilježen je poluvijek od približno 6,2 do 8,7 sati nakon višestrukih doza epoetina alfa primijenjenih intravenski.
A handheld gamma counter (represented by any handheld gamma detection probe) was used intraoperatively to identify sentinel lymph nodes localising technetium Tc 99m.
Ručni gama brojač (bilo koja ručna sonda za otkrivanje gama zračenja) korišten je intraoperativno za identifikaciju limfnih čvorova čuvara lokaliziranih tehnecijem Tc 99m.
A hard lump and warmth at the injection site
Tvrda oteklina i toplina na mjestu injiciranja
a hazard ratio (TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease free survival compared to FAC.
omjer hazarda (TAC/FAC) manji od 1 prikazuje da je TAC povezan sa dužim preživljenjem bez znakova bolesti u usporedbi sa FAC-om.
a Hazard ratio and p-value based on the Cox Model adjusted for PSA (ln) and LDH (ln) and stratified by bisphosphonate use, number of bone metastases, and primary Gleason grade. b Hazard ratio based on the unadjusted Cox Model. c p-value based on a log-rank test.
a Omjer rizika i p-vrijednost temeljeni na Cox modelu prilagođenom za PSA (ln) i LDH (ln) i stratificirani po uporabi bisfosfonata, broju koštanih presadnica i primarnom Gleason stupnju. b Omjer rizika temeljen na Cox modelu. c p-vrijednost temeljena na log rank testu.
A hazard ratio favouring sunitinib was observed in all subgroups of baseline characteristics evaluated, including an analysis by number of prior systemic therapies.
Omjer rizika u prilog sunitinibu zabilježen je u svim podskupinama ocijenjenima na temelju početnih obilježja, uključujući i analizu prema broju prethodnih sustavnih terapija.
A hazard ratio less than 1 indicates an advantage for VMP
Omjer hazarda manji od 1 pokazuje da VMP ima prednost. c Nominalna p-vrijednost utemeljena na stratificiranom log-rank testu prilagođenom za čimbenike stratifikacije:
A hazard ratio of less than 1 favors docetaxel + cisplatin + 5-FU
Omjer hazarda manji od 1 daje prednost kombinaciji docetaksel + cisplatin + 5-FU
A hazard ratio of less than 1 favors docetaxel + cisplatin + fluorouracil
Omjer hazarda manji od 1 daje prednost kombinaciji docetaksel + cisplatin + fluorouracil
A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU
Omjer hazarda manji od 1 daje prednost kombinaciji docetaksel + cisplatin + 5-FU
A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU
Omjer rizika manji od 1 daje prednost kombinaciji docetaksel + cisplatin + 5-FU
A Hazard ratio of less than 1 favours docetaxel + cisplatin + fluorouracil
Omjer hazarda manji od 1 daje prednost kombinaciji docetaksel + cisplatin + fluorouracil
A hazard ratio of less than 1 favours docetaxel + cisplatin + fluorouracil
Omjer rizika manji od 1 daje prednost kombinaciji docetaksel + cisplatin + fluorouracil
a head injury
ozljedu glave
A heart attack - symptoms will usually include pain, including chest pain spreading to the jaw, neck and upper arm.
Srčani udar - simptomi obično uključuju bol, uključujući bol u prsnom košu koja se širi u čeljust, vrat i gornji dio ruke.
a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels
rčani udar ili bilo koju drugu bolest srca uključujući srčane aritmije, ili bolest krvnih žila
A heart attack within the last four weeks.
Srčani udar u roku posljednjih četiri tjedna.
a heart attack within the last six months,
rčani udar unutar posljednjih šest mjeseci,
a heart attack, heart beat problems, circulation or breathing problems
rčani udar, probleme s otkucajima srca, cirkulacijom ili disanjem
a heart attack, or unstable angina (angina or chest pain that is not well controlled).
rčani udar, ili nestabilnu anginu (anginu ili bol u prsima koja nije dobro kontrolirana).
a Heart rate less than 60 beats per minutes (bpm) b Permanently discontinue in the event of recurrence.
a Srčana frekvencija niža od 60 otkucaja u minuti b Trajno prekinuti primjenu u slučaju ponovne pojave.
a heart rhythm disorder, abnormal pulse
poremećaj srčanog ritma, abnormalan puls
a heart rhythm problem called ‘bundle branch block’
problem sa srčanim ritmom zvan “blok grane”
a heart rhythm problem called ‘“bundle branch block”’
problem sa srčanim ritmom zvan “blok grane”
A hepatic impairment trial was performed in non-cancer subjects administered a single dose of 140 mg of medicinal product under fasting conditions.
U ispitanika s oštećenjem jetre koji nemaju rak bilo je provedeno ispitivanje, pri čemu je lijek primijenjen u jednokratnoj dozi od 140 mg u stanju gladovanja.
a hernia of the tube that carries food to your stomach low haemoglobin or red blood cell count (anaemia)
kila jednjaka (cijevi kojom se hrana prenosi u želudac) niska razina hemoglobina ili malen broj crvenih krvnih stanica (anemija).
A heterologous booster vaccination with a 7.5 µg non-adjuvanted formulation of the A/Indonesia/05/2005 strain vaccine has been administered in a time frame of 12 to 24 months after priming vaccination with two doses of the A/Vietnam/1203/2004 strain vaccine in three clinical studies in adults aged 18 to 59 years and in older people aged 60 years and above.
Heterologno booster-cijepljenje sa 7,5 µg neadjuventirane formulacije cjepiva sa sojem A/Indonesia/05/2005, primijenjeno je u vremenskom okviru od 12 do 24 mjeseca nakon primarnog cijepljenja s dvije doze cjepiva soja A/Vietnam/1203/2004, u tri klinička ispitivanja u odraslih osoba od 18 do 59 godina i starijih osoba od 60 i više godina.
A high fat meal did not affect the Cmax and AUC of oral palonosetron.
Obrok s visokim sadržajem masti nije utjecao na Cmax i AUC oralnog palonosetrona.
A high incidence of severe diarrhoea was observed when panitumumab was administered in combination with IFL (see section 4.4), and increased toxicity and deaths were seen when panitumumab was combined with bevacizumab and chemotherapy (see sections 4.4 and 5.1).
Visoka incidencija teških proljeva bila je primijećena pri primjeni panitumumaba u kombinaciji s kemoterapijom IFL-om (vidjeti dio 4.4), a povećana toksičnost i smrtnost primijećeni su kad je panitumumab bio kombiniran s bevacizumabom i kemoterapijom (vidjeti dio 4.4 i 5.1).
a high level of alkaline phosphatase in your blood
visoka razina alkalne fosfataze u krvi
a high level of fat in your blood (triglycerides) fluid retention due to cardiac or kidney problems
visoka razina masnoća u krvi (triglicerida) zadržavanje tekućine u tijelu zbog problema sa srcem ili bubrezima
a High Level Term b Observed in open-label studies c Observed during post-marketing d Observed in 2011 data pool of double-blind placebo-controlled studies e Observed in studies performed in patients with Parkinson’s disease Description of selected adverse reactions
aPojam visoke razine bOpaženo u otvorenim studijama cOpaženo tijekom postmarketinškog razdoblja dOpaženo u objedinjenim podacima dvostruko slijepih placebo kontroliranih ispitivanja iz 2011.g. eOpaženo u ispitivanjima provedenim na bolesnicima s Parkinsonovom bolesti Opis izdvojenih nuspojava
a High Level Term b Observed in open-label studies c Observed during post-marketing d Observed in 2011 data pool of double-blind placebo-controlled studies e Observed in studies performed in patients with Parkinson’s disease Description of selected adverse reactions
aPojam visoke razine bOpaženo u otvorenim studijama cOpaženo tijekom postmarketinškog razdoblja dOpaženo u objedinjenim podacima dvostruko slijepih placebom kontroliranih ispitivanja iz 2011.g. eOpaženo u ispitivanjima provedenim na bolesnicima s Parkinsonovom bolesti Opis izdvojenih nuspojava
A high number of circulating lymphocytes (> 400,000/mcL) may confer increased risk.
Visok broj limfocita (> 400 000/μl) u cirkulaciji može doprinjeti povećanom riziku.
A high proportion of patients (approximately 62%) went on to receive a variety of non-protocol specified anti- cancer therapies, which may have impacted the analysis of overall survival.
Visok udio bolesnika (oko 62%) je u nastavku liječenja primao različite antitumorske lijekove koji nisu navedeni u protokolu, a koji su mogli utjecati na analizu ukupnog preživljenja.
A high proportion of patients (approximately 63% IFN/placebo; 55% Avastin/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival.
Velik udio bolesnika (oko 63% za IFN/placebo; 55% za Avastin/IFN) je nakon završetka ispitivanja primao različite nespecificirane antitumorske terapije, uključujući antineoplastičke lijekove, što je moglo utjecati na analizu ukupnog preživljenja.
A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
Visoki rizik od arterijske tromboembolije zbog prisutnosti većeg broja čimbenika rizika (vidjeti dio 4.4) ili jednog ozbiljnog čimbenika rizika kao što je:
A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
Visoki rizik od arterijske tromboembolije zbog prisutnosti višestrukih čimbenika rizika (vidjeti dio 4.4) ili prisutnost jednog ozbiljnog čimbenika rizika kao što je:
A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4).
Visoki rizik od venske tromboembolije zbog prisutnosti višestrukih čimbenika rizika (vidjeti dio 4.4).
A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4);
Visoki rizik od venske tromboembolije zbog prisutnosti višestrukih čimbenika rizika (vidjeti dio 4.4).
a high temperature (fever)
povišenu tjelesnu temperaturu (vrućica)
a high temperature (fever)
visoku tjelesnu temperaturu (vrućicu)
A high-fat meal reduced crizotinib AUCinf and Cmax by approximately 14% when a 250 mg single dose was given to healthy volunteers.
Primjena jedne doze od 250 mg u zdravih dobrovoljaca a uz punomastan obrok smanjila je AUCinf i Cmax krizotiniba za približno 14%.
A high-fat, high-calorie meal delays the absorption of levodopa by two hours.
Visokokalorični obrok s visokim udjelom masnoće odgađa apsorpciju levodope do dva sata.
A higher anti-FXa/FIIa activity was observed after dabigatran etexilate administration with enoxaparin pre-treatment compared to that after treatment with dabigatran etexilate alone.
Veća anti-FXa/FIIa- aktivnost primijećena je uz primjenu dabigatraneteksilata nakon prethodnog liječenja enoksaparinom nego uz sam dabigatraneteksilat.
A higher dose may be needed in children.
U djece bi mogla biti potrebna veća doza.
A higher dose of bupropion may be required to obtain the desired clinical effect.
da bi se postigao željeni klinički učinak.
A higher dose of ibuprofen may be required
Može biti potrebna viša doza rifabutina da
A higher dose of these antidepressants may
Može biti potrebna viša doza antidepresiva
A higher dose of these proton pump
Može biti potrebna viša doza inhibitora
A higher dose of umeclidinium/vilanterol (113/22 micrograms) was also studied in a 24-week placebo controlled clinical study and in two of the three 24-week active-controlled studies.
Viša doza umeklidinija/vilanterola (113/22 mikrograma) također je ispitana u jednom 24-tjednom placebom kontroliranom ispitivanju te u dvama od triju 24-tjednih ispitivanja kontroliranih aktivnim lijekom.
A higher frequency of adverse reactions (eg, dizziness, nausea, paraesthesia) and laboratory abnormalities (elevated liver enzymes) have been observed when efavirenz is co-administered with ritonavir dosed as an antiretroviral agent.
Zamijećena je veća učestalost nuspojava (npr. omaglica, mučnina, parestezija) i laboratorijskih poremećaja (porast vrijednosti jetrenih enzima) kada se efavirenz davao istodobno s ritonavirom kao antiretrovirusnim lijekom.
A higher incidence has been observed in patients of Japanese origin (see section 4.4)
Veća incidencija je uočena među bolesnicima japanskog porijekla (vidjeti dio 4.4)
A higher incidence has been observed in patients of Japanese origin (see section 4.4).
Veća incidencija je uočena među bolesnicima japanskog porijekla (vidjeti dio 4.4)
A higher incidence of adverse reactions cannot be ruled out.
Ne može se isključiti mogućnost veće incidencije nuspojava.
A higher incidence of hand foot skin reaction (HFSR) / palmar-plantar erythrodysesthesia syndrome, severe liver function test abnormalities and hepatic dysfunction was observed in Asian (in particular Japanese) patients treated with Stivarga compared with Caucasians.
U bolesnika azijskog podrijetla (osobito Japanaca) liječenih lijekom Stivarga opažena je viša incidencija kožne reakcije na šakama i stopalima / sindroma palmarno- plantarne eritrodizestezije, teških poremećaja rezultata testova jetrene funkcije i poremećaja funkcije jetre u usporedbi s bijelcima.
A higher incidence of ILD (approximately 5% with a mortality rate of 1.5%) is seen among patients with Japanese origin.
Veća incidencija IBP (oko 5% sa stopom smrtnosti od 1,5%) uočena je među bolesnicima japanskog porijekla.
A higher incidence of skin laceration may be attributable to more vigorous finger extension procedures in patients after receiving anesthesia to the hand.
Viša incidencija laceracije kože može se pripisati žustrijim postupcima ekstenzije prsta u bolesnika nakon što su dobili anesteziju u šaku.
A higher incidence of weight decrease, decreased appetite, headache and depression was observed during Study RO-2455-404-RD in patients receiving concomitant roflumilast and long-acting muscarinic antagonists (LAMA) plus concomitant inhaled corticosteroids (ICS) and long acting B2 agonists (LABA) compared to those treated only with concomitant roflumilast, ICS and LABA.
U ispitivanju RO-2455-404-RD je u bolesnika koji su istodobno uzimali roflumilast i dugodjelujuće muskarinske antagoniste (engl. long acting muscarinic antagonists, LAMA) uz inhalacijske kortikosteroide (engl. inhaled corticosteroids, ICS) i dugodjelujuće β2 agoniste (engl. long acting B2 agonists, LABA) zabilježena veća incidencija smanjenja težine, smanjenog apetita, glavobolje i depresije u usporedbi s onima koji su istodobno uzimali samo roflumilast, ICS i LABA.
A higher incidence rate of hypoglycemia events was reported in patients with pNET in comparison to MRCC and GIST.
Viša stopa incidencije događaja hipoglikemije prijavljena je u bolesnika s pNET-om u usporedbi s onima s MRCC-om i GIST-om.
A higher median dose of Nuwiq was required to treat bleedings in children (43.9 IU/kg) than in adults (33.0 IU/kg), and a higher median dose was required to treat moderate to major than minor bleedings (78.2 IU/kg vs.
Veći medijan doze lijeka Nuwiq bio je potreban za liječenje krvarenja u djece (43,9 IU/kg) u odnosu na odrasle (33,0 IU/kg) te je veći medijan doze bio potreban za liječenje srednjih do obilnih krvarenja u odnosu na slabija krvarenja (78,2 IU/kg naspram 41,7 IU/kg).
A higher percentage of patients receiving Ultibro Breezhaler responded with a clinically meaningful improvement in SGRQ score (defined as a decrease of at least 4 units from baseline) at week 26 compared to placebo (63.7% and 56.6% respectively, p=0.088) and tiotropium (63.7% Ultibro Breezhaler vs.
Viši postotak bolesnika koji su primali Ultibro Breezhaler odgovorio je s klinički značajnim poboljšanjem rezultata SGRQ-a (definiranim kao smanjenje od najmanje 4 jedinice u odnosu na početnu vrijednost) u 26 tjednu u usporedbi s placebom (63,7% odnosno 56,6%, p=0,088) i tiotropijem (63,7% Ultibro Breezhaler vs.
A higher percentage of patients receiving Ulunar Breezhaler responded with a clinically meaningful improvement in SGRQ score (defined as a decrease of at least 4 units from baseline) at week 26 compared to placebo (63.7% and 56.6% respectively, p=0.088) and tiotropium (63.7% Ulunar Breezhaler vs.
Viši postotak bolesnika koji su primali Ulunar Breezhaler odgovorio je s klinički značajnim poboljšanjem rezultata SGRQ-a (definiranim kao smanjenje od najmanje 4 jedinice u odnosu na početnu vrijednost) u 26 tjednu u usporedbi s placebom (63,7% odnosno 56,6%, p=0,088) i tiotropijem (63,7% Ulunar Breezhaler vs.
A higher percentage of patients receiving Xoterna Breezhaler responded with a clinically meaningful improvement in SGRQ score (defined as a decrease of at least 4 units from baseline) at week 26 compared to placebo (63.7% and 56.6% respectively, p=0.088) and tiotropium (63.7% Xoterna Breezhaler vs.
Viši postotak bolesnika koji su primali Xoterna Breezhaler odgovorio je s klinički značajnim poboljšanjem rezultata SGRQ-a (definiranim kao smanjenje od najmanje 4 jedinice u odnosu na početnu vrijednost) u 26 tjednu u usporedbi s placebom (63,7% odnosno 56,6%, p=0,088) i tiotropijem (63,7% Xoterna Breezhaler vs.
A higher proportion of JETREA treated patients gained ≥ 2 or ≥ 3 lines in BCVA (irrespective of vitrectomy) at Month 6 (28.0% and 12.3%, respectively) compared with patients treated with placebo (17.1% and 6.4%) (p=0.003 and p=0.024, respectively).
Veći udio bolesnika liječenih JETREOM dobili su ≥ 2 ili ≥ 3 reda BCVA (bez obzira na vitrektomiju) u 6. mjesecu ( 28,0% i 12,3% redom) u usporedbi s bolesnicima liječenim placebom (17,1% i 6,4%) (redom, p=0,003 i p=0,024).
A higher proportion of patients demonstrated clinically meaningful response at week 26 on Ultibro Breezhaler as compared to tiotropium (68.1% Ultibro Breezhaler versus 59.2% tiotropium, p=0.016) and fluticasone/salmeterol (65.1% Ultibro Breezhaler versus 55.5% fluticasone/salmeterol, p=0.088).
Veći udio bolesnika pokazao je klinički značajan odgovor u 26 tjednu uz Ultibro Breezhaler u usporedbi s tiotropijem (68,1% Ultibro Breezhaler naspram 59,2% tiotropij, p=0,016) i flutikazonom/salmeterolom (65,1% Ultibro Breezhaler naspram 55,5% flutikazon/salmeterol, p=0,088).
A higher proportion of patients demonstrated clinically meaningful response at week 26 on Ulunar Breezhaler as compared to tiotropium (68.1% Ulunar Breezhaler versus 59.2% tiotropium, p=0.016) and fluticasone/salmeterol (65.1% Ulunar Breezhaler versus 55.5% fluticasone/salmeterol, p=0.088).
Veći udio bolesnika pokazao je klinički značajan odgovor u 26 tjednu uz Ulunar Breezhaler u usporedbi s tiotropijem (68,1% Ulunar Breezhaler naspram 59,2% tiotropij, p=0,016) i flutikazonom/salmeterolom (65,1% Ulunar Breezhaler naspram 55,5% flutikazon/salmeterol, p=0,088).
A higher proportion of patients demonstrated clinically meaningful response at week 26 on Xoterna Breezhaler as compared to tiotropium (68.1% Xoterna Breezhaler versus 59.2% tiotropium, p=0.016) and fluticasone/salmeterol (65.1% Xoterna Breezhaler versus 55.5% fluticasone/salmeterol, p=0.088).
Veći udio bolesnika pokazao je klinički značajan odgovor u 26 tjednu uz Xoterna Breezhaler u usporedbi s tiotropijem (68,1% Xoterna Breezhaler naspram 59,2% tiotropij, p=0,016) i flutikazonom/salmeterolom (65,1% Xoterna Breezhaler naspram 55,5% flutikazon/salmeterol, p=0,088).
A higher proportion of patients treated with ustekinumab who had spondylitis with peripheral arthritis as their primary presentation, demonstrated 50 and
Veći udio bolesnika liječenih ustekinumabom koji su na početku imali spondilitis sa perifernim artritisom, pokazali su 50% i 70%- tno poboljšanje u BASDAI bodovima (engl.
A higher rate for skin laceration has been shown following two concurrent injections in the same hand in a controlled post-marketing trial (see also Section 4.8).
Kontrolirano ispitivanje nakon stavljanja lijeka u promet pokazalo je da je stopa laceracije kože viša nakon istovremene primjene dvije injekcije u istu šaku (vidjeti također dio 4.8).
A higher rate of infections was observed with lenalidomide in combination with dexamethasone than with MPT.
Viša stopa infekcija opažena je uz lenalidomid u kombinaciji s deksametazonom nego uz MPT.
A higher rate of major birth defects was observed in an observational study comparing pregnancies exposed to etanercept during the first trimester, with pregnancies not exposed to etanercept or other TNF-antagonists (adjusted odds ratio 2.4, 95% CI: 1.0- 5.5).
U opservacijskom ispitivanju koje je uspoređivalo trudnoće koje su bile izložene etanerceptu tijekom prvog tromjesečja sa trudnoćama koje nisu bile izložene etanerceptu ili drugim antagonistima TNF-a, zabilježena je viša stopa velikih prirođenih mana (prilagođen omjer izgleda 2,4; 95% CI: 1,0-5,5).
A higher risk of renal impairment has been reported in HIV-1 infected patients receiving tenofovir disoproxil fumarate in combination with a ritonavir or cobicistat boosted protease inhibitor.
U pacijenata zaraženih virusom HIV-1 koji su primali tenofovirdizoproksilfumarat u kombinaciji s ritonavirom ili kobicistatom pojačanim inhibitorom proteaze zabilježen je veći rizik od oštećenja funkcije bubrega.
A higher risk of renal impairment has been reported in HIV-1 infected patients receiving tenofovir disoproxil in combination with a ritonavir or cobicistat boosted protease inhibitor.
Veći rizik od oštećenja bubrežne funkcije zabilježen je u bolesnika zaraženih virusom HIV-1 koji primaju tenofovirdizoproksil u kombinaciji s inhibitorom proteaze pojačanim ritonavirom ili kobicistatom.
A higher risk of renal impairment has been reported in patients receiving tenofovir disoproxil fumarate in combination with a ritonavir or cobicistat boosted protease inhibitor.
Veći rizik od oštećenja funkcije bubrega zabilježen je u pacijenata koji primaju tenofovirdizoproksilfumarat u kombinaciji s inhibitorom proteaze pojačanim ritonavirom ili kobicistatom.
A higher starting dose of 7 mg/m2 is recommended for patients 1 to less than 3 years of age based on pharmacokinetic simulations (see section 5.2).
Viša početna doza od 7 mg/m2 preporučena je za bolesnike u dobi od 1 godine do mlađe od 3 godine na temelju farmakokinetičkih simulacija (vidjeti dio 5.2).
A higher starting dose of 7 mg/m2 is therefore recommended for patients 1 to less than 3 years of age (see section 4.2).
Stoga se viša početna doza od 7 mg/m2 preporučuje za bolesnike u dobi od 1 godine do mlađe od 3 godine (vidjeti dio 4.2).
a history of alcohol abuse
anamnezu zlouporabe alkohola
a history of an irregular heart beat (arrhythmias)
ako imate nepravilne otkucaje srca (aritmije) u povijesti bolesti
A history of anaphylaxis unrelated to omalizumab may be a risk factor for anaphylaxis following Xolair administration.
Prethodna pojava anafilaksije koja nije bila povezana s omalizumabom može biti čimbenik rizika za pojavu anafilaksije nakon primjene Xolaira.
a history of bleeding diathesis
hemoragijskom dijatezom u povijesti bolesti
a history of blood clots in your blood vessels
anamnezu krvnih ugrušaka u krvnim žilama
A history of blood clots in your veins
Krvni ugrušci u venama u povijesti bolesti
A history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
Kronična ili teška konstipacija, ili posljedice konstipacije, ili utvrđena ili suspektna mehanička gastrointestinalna opstrukcija u anamnezi.
A history of endometrial hyperplasia (see below)
hiperplaziju endometrija u anamnezi (vidjeti ispod)
A history of febrile convulsions, a family history of convulsions, or Sudden Infant Death Syndrome (SIDS) do not constitute a contraindication for the use of Vaxelis.
Povijest febrilnih konvulzija, obiteljska povijest konvulzija ili sindrom iznenadne dojenačke smrti (SIDS) ne smatraju se kontraindikacijom za primjenu cjepiva Vaxelis.
A history of fits (convulsions)
nekada ste imali napadaje (konvulzije)